In this retrospective study, the medical records of 28 patients with nAMD treated with at least 3 consecutive monthly injections of ranibizumab (0.5 mg/0.05 mL) or aflibercept (2mg /0.05 mL) between December 2013 and June 2014 and who were followed up for at least 3 months were reviewed. Subfoveal choroidal thickness was measured using enhanced-depth-imaging optical coherence tomography
Choroidal thickness changes after intravitreal anti-VEGF therapy for age-related macular degeneration: ranibizumab versus aflibercept / Gharbiya, Magda. - In: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. - ISSN 0146-0404. - STAMPA. - 56:7(2015), pp. 1507-1507. (Intervento presentato al convegno Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) tenutosi a Denver, CO nel MAY 03-07, 2015).
Choroidal thickness changes after intravitreal anti-VEGF therapy for age-related macular degeneration: ranibizumab versus aflibercept
GHARBIYA, Magda
Primo
2015
Abstract
In this retrospective study, the medical records of 28 patients with nAMD treated with at least 3 consecutive monthly injections of ranibizumab (0.5 mg/0.05 mL) or aflibercept (2mg /0.05 mL) between December 2013 and June 2014 and who were followed up for at least 3 months were reviewed. Subfoveal choroidal thickness was measured using enhanced-depth-imaging optical coherence tomography| File | Dimensione | Formato | |
|---|---|---|---|
|
Gharbiya_Choroidal Thickness_2015.pdf
accesso aperto
Note: https://iovs.arvojournals.org/article.aspx?articleid=2331216
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
40.19 kB
Formato
Adobe PDF
|
40.19 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
